RT Journal Article
SR Electronic
T1 Differentiation of SARS-CoV-2 naturally infected and vaccinated individuals in an inner-city emergency department
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.13.21264968
DO 10.1101/2021.10.13.21264968
A1 Beck, Evan J
A1 Hsieh, Yu-Hsiang
A1 Fernandez, Reinaldo E
A1 Dashler, Gaby
A1 Egbert, Emily R
A1 Truelove, Shawn A
A1 Garliss, Caroline
A1 Wang, Richard
A1 Bloch, Evan M.
A1 Shrestha, Ruchee
A1 Blankson, Joel
A1 Cox, Andrea L.
A1 Manabe, Yukari C
A1 Kickler, Thomas
A1 Rothman, Richard E
A1 Redd, Andrew D
A1 Tobian, Aaron AR
A1 Milstone, Aaron M
A1 Quinn, Thomas C
A1 Laeyendecker, Oliver
YR 2021
UL http://medrxiv.org/content/early/2021/10/14/2021.10.13.21264968.abstract
AB Background Emergency Departments (EDs) can serve as surveillance sites for infectious diseases. Our purpose was to determine the burden of SARS-CoV-2 infection and prevalence of vaccination against COVID-19 among patients attending an urban ED in Baltimore City.Methods Using 1914 samples of known exposure status, we developed an algorithm to differentiate previously infected, vaccinated, and unexposed individuals using a combination of antibody assays. We applied this testing algorithm to 4360 samples ED patients obtained in the springs of 2020 and 2021. Using multinomial logistic regression, we determined factors associated with infection and vaccination.Results For the algorithm, sensitivity and specificity for identifying vaccinated individuals was 100% and 99%, respectively, and 84% and 100% for naturally infected individuals. Among the ED subjects, seroprevalence to SARS-CoV-2 increased from 2% to 24% between April 2020 and March 2021. Vaccination prevalence rose to 11% by mid-March 2021. Marked differences in burden of disease and vaccination coverage were seen by sex, race, and ethnicity. Hispanic patients, though 7% of the study population, had the highest relative burden of disease (17% of total infections) but similar vaccination rates. Women and White individuals were more likely to be vaccinated than men or Black individuals (adjusted odds ratios [aOR] 1.35 [95% CI: 1.02, 1.80] and aOR 2.26 [95% CI: 1.67, 3.07], respectively).Conclusions Individuals previously infected with SARS-CoV-2 can be differentiated from vaccinated individuals using a serologic testing algorithm. SARS-CoV-2 exposure and vaccination uptake frequencies reflect gender, race and ethnic health disparities in this urban context.Summary Using an antibody testing algorithm, we distinguished between immune responses from SARS-CoV-2-infected and vaccinated individuals. When applied to blood samples from an emergency department in Baltimore, disparities in disease burden and vaccine uptake by sex, race, and ethnicity were identified.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). Other support was provided by extramural support from NIAID [R01AI120938, R01AI120938S1, and R01AI128779, K01AI100681, UM1‐AI068613]; the NIH Center of Excellence in Influenza Research and Surveillance [HHSN272201400007C]; and the National Heart Lung and Blood Institute [K23HL151826].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Johns Hopkins University School of Medicine Institutional Review Board of the Johns Hopkins University School of Medicine gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors